ORY Oryzon Genomics

Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)

Edison Investment Research Limited
Edison Investment Research Limited: Edison issues outlook on Oryzon Genomics (ORY)

20-Jan-2020 / 10:01 GMT/BST

 

London, UK, 20 January 2020

Edison issues outlook on Oryzon Genomics (ORY)

As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa clinical trials with both assets at eight conferences last year. All readouts were still interim. This and the fact that Phase IIa trials, in general, are relatively small and focus on safety meant that the share price did not reach new highs despite all readouts being positive. Final results from the trials are expected throughout 2020-21 and Oryzon is already initiating a Phase IIb trial with its CNS asset in borderline personality disorder (BPD). This will provide plenty more catalysts in the coming months. Our valuation is slightly higher at €454m or €9.9/share.

 

Our valuation of Oryzon is slightly higher at €454m or €9.9 per share, up from €437m or €9.5 per share, mainly due to rolling our model forward. We leave our assumptions unchanged. The main near-term catalysts include vafidemstat Phase IIa REIMAGINE-AD data from AD patients in Q220; vafidemstat Phase IIa ETHERAL EU six-month interim trial results in H120; updated data from iadademstat Phase IIa CLEPSIDRA in SCLC and Phase IIa ALICE in AML some time in 2020.


to view the full report.

 

to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the .

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Jonas Peciulis, +44 (0)20 3077 5728

 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

956701  20-Jan-2020 

fncls.ssp?fn=show_t_gif&application_id=956701&application_name=news&site_id=research_pool
EN
20/01/2020

Underlying

ORYOryzon Genomics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oryzon Genomics

 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON Reports Financial Results and Corporate Update for Quarter Ende...

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in aggression in BPDOngoing expansion of Phase IIb schizophrenia trial into additional EU countriesFinalizing preparations for new Phase II trial in aggression in autism spectrum disorder as a part of the IPCEI EU Grant in personalized medicine Oncology – Hema...

February 27, 2026 1 EN
 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON Receives European Medicines Agency Approval to Initiate a Phase...

ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, for th...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON to Participate in Upcoming Events in February and March

ORYZON to Participate in Upcoming Events in February and March MADRID and CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: Bio-Neuroscience 2026, February 24-27Location: Hotel Jakarta, Amsterdam SmallCap Event 20th Edition, March 17Location: Les Salons Hoche, Paris BIO-Europe Spring 2026, March 23-25Location: Feira Internacional de Lisboa (FIL), Lisbon LSX World Congr...

February 19, 2026 1 EN
 PRESS RELEASE
Free
ORY ORYZON GENOMICS

ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as C...

ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with mor...

February 12, 2026 1 EN
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
02/10/26 February 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch